Meeting
2021 ASCO Annual Meeting
A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
Authors
Gustav J. Ullenhag
Akademiska Sjukhus, Uppsala, Sweden
Gustav J. Ullenhag , Jeffrey Yachnin , Ana Carneiro , Emma Elison , Malin Carlsson , Charlotte Astrid Russell , Karin Enell Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Clinical Trial Registration Number
NCT04144842
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2646)
DOI
10.1200/JCO.2021.39.15_suppl.2646
Abstract #
2646
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2022 ASCO Annual Meeting
First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.
First Author: R. Donald Harvey
Poster
2022 ASCO Annual Meeting
Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
First Author: Gustav J. Ullenhag
Poster
2019 ASCO Annual Meeting
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
First Author: Jian-Ming Xu